TrialThe Journal of dermatology2020

Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanoma.

Kenjiro Namikawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.